MOLOGEN AG announced that it has entered into a collaboration agreement with the Danish Aarhus University Hospital. The agreement relates to an early stage trial with MOLOGEN's immunomodulator MGN1703 in HIV (Human Immunodeficiency Virus) patients. Thus the potential range of applications of the product could be expanded.

The aim of the so-called TEACH study is to see if the immunotherapy with MGN1703 can activate the innate and adaptive immune system in HIV patients, to enhance killing of the HIV infected cells. Aarhus University Hospital will conduct the trial in two hospital centers in Denmark and already received respective funding from the American Foundation for AIDS research (amfAR). MOLOGEN will provide the immunomodulator MGN1703.

The study is planned to start within the next few weeks. MGN1703 is currently being investigated in the registration trial IMPALA in colorectal cancer and in the randomized trial IMPULSE in small cell lung cancer. Both studies are currently enrolling patients.